2024年美[měi]國臨床[chuánɡ]腫瘤學[xué]會年會（American Society of Clinical Oncology，ASCO）將于5月[yuè]31日[rì]至6月[yuè]4日在[zài]美國芝[zhī]加哥舉行，榮昌生[shēnɡ]物（股[ɡǔ]票代碼：688331.SH / 09995.HK）將攜[xié]重磅研[yán]究成果[ɡuǒ]再次登[dēnɡ]上這一[yī]頂尖國際學術舞臺，唱響中國創[chuànɡ]新藥好[hǎo]聲音，展示[shì]開創性[xìnɡ]新治療[liáo]手段的[de]“中國方案”。
在本次[cì]大會上[shànɡ]，榮[rónɡ]昌生物[wù]原創原[yuán]研的我[wǒ]國首個[ɡè]獲批上[shànɡ]市的國產抗體偶聯（ADC）藥物[wù]維迪西[xī]妥單抗[kànɡ]、靶[bǎ]向間皮[pí]素（MSLN）ADC藥物[wù]RC88等兩款創新[xīn]藥的16項最[zuì]新臨床[chuánɡ]研究數據，將精彩[cǎi]亮相，具[jù]體包括[kuò]1項臨床科學[xué]研討、5項壁報展[zhǎn]示、10項線上摘要[yào]，覆[fù]蓋胃癌[ái]、膀胱癌[ái]、婦瘤等[děnɡ]多個癌[ái]種，不僅[jǐn]有單藥還有多[duō]種聯合[hé]療法。讓我們搶[qiǎnɡ]先看看[kàn]榮昌生[shēnɡ]物入選本屆ASCO大會的[de]“豪華陣容”！
1項臨床科學[xué]研討
Efficacy of disitamab vedotin (RC48) plus tislelizumab and S-1 as first-line therapy for HER2-overexpressing advanced stomach or gastroesophageal junction adenocarcinoma: A multicenter, single-arm, phase II trial (RCTS).
摘要編號：#4009
展示形[xínɡ]式：臨床科[kē]學研討會
展示時[shí]間：6月2日下午[wǔ]4:30（美[měi]國東部[bù]時間）
第一作[zuò]者：劉聯教[jiào]授 山[shān]東大學[xué]齊魯醫院
5項壁[bì]報展示[shì]
01
RC88在卵[luǎn]巢癌、非[fēi]鱗狀非[fēi]小細胞[bāo]肺癌和[hé]宮頸癌[ái]患者中[zhōnɡ]的療效[xiào]和安全[quán]性：一[yī]項首次[cì]人體1/2期[qī]臨床研[yán]究的結果
The efficacy and safety of RC88 in patients with ovarian cancer, non-squamous-non-small-cell lung-carcinoma and cervical cancer: Results from a first-in-human phase 1/2 study.
摘要編號：#5551
壁報編號：#422
展示形[xínɡ]式：壁報展[zhǎn]示
展示時[shí]間：6月3日上午[wǔ]9:00（美[měi]國東部[bù]時間）
第一作[zuò]者：劉雨桃[táo]教授 中國醫學科學[xué]院腫瘤[liú]醫院
02
RC48-C017的初步[bù]療效和[hé]安全性[xìnɡ]結果：一項針對HER2表[biǎo]達的肌[jī]層浸潤[rùn]性膀胱[ɡuānɡ]癌(MIBC)患者[zhě]使用維迪西妥[tuǒ]單抗聯合特瑞[ruì]普利單抗進行[xínɡ]新輔助[zhù]治療的[de]II期[qī]研究
Preliminary efficacy and safety results from RC48-C017: A phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with muscle invasive bladder cancer (MIBC) with HER2 expression.
摘要編號：#4568
壁報編號：#263
展示形[xínɡ]式：壁報展[zhǎn]示
展示時[shí]間：6月2日上午[wǔ]9:00（美[měi]國東部[bù]時間）
第一作[zuò]者：盛錫楠[nán]教授 北京大[dà]學腫瘤[liú]醫院
03
Adjuvant or rescue disitamab vedotin (RC48-ADC) for high-risk non-muscle invasive bladder cancer with HER2 overexpression: A phase II multi-center study.
摘要編號：#TPS4625
壁報編號：#311a
展示形[xínɡ]式：壁報展[zhǎn]示
展示時[shí]間：6月2日上午[wǔ]9:00（美[měi]國東部[bù]時間）
主要研[yán]究者：曾浩教[jiào]授 四[sì]川大學[xué]華西醫院
第一作[zuò]者：陳俊儒[rú]教授 四川大[dà]學華西[xī]醫院
04
評價維迪西妥[tuǒ]單抗治[zhì]療HER2表[biǎo]達的2L復發[fā]或轉移[yí]性宮頸癌(r/mCC)有[yǒu]效性和[hé]安全性[xìnɡ]：RC48-C018的中[zhōnɡ]期結果[ɡuǒ]
Evaluation of the effectiveness and safety of disitamab vedotin in HER2-expressing 2L recurrent or metastatic cervical cancer (r/mCC): Interim results of RC48-C018.
摘要編號：#5528
壁報編號：#399
展示形[xínɡ]式：壁報展[zhǎn]示
展示時[shí]間：6月3日上午[wǔ]9:00（美[měi]國東部[bù]時間）
第一作[zuò]者：袁光文[wén]教授 中國醫學科學[xué]院腫瘤[liú]醫院
05
一項前瞻性、單臂、單中心臨床研究[jiū]：維迪[dí]西妥單抗聯合[hé]特瑞普[pǔ]利單抗[kànɡ]治療進展或對順鉑化[huà]療不耐[nai]受的晚[wǎn]期陰莖癌患者[zhě]
SAVE: A prospective, single-arm, single-center clinical study of disitamab vedotin in combination with toripalimab in patients with advanced penile cancer that has progressed or is intolerant to cisplatin chemotherapy.
摘要編號：#TPS5107
壁報編號：#513a
展示形[xínɡ]式：壁報展[zhǎn]示
展示時[shí]間：6月2日上午[wǔ]9:00（美[měi]國東部[bù]時間）
第一作[zuò]者：袁方教[jiào]授 重[zhònɡ]慶大學[xué]附屬腫瘤醫院[yuàn]
10項線上摘[zhāi]要
#e13011評價維迪西妥[tuǒ]單抗在[zài]HER-2表[biǎo]達的乳[rǔ]腺癌中[zhōnɡ]的療效[xiào]與安全[quán]性：一[yī]項多中[zhōnɡ]心回顧性研究[jiū]
Efficacy and safety of disitamab vedotin (RC48) in HER2-expressing breast cancer: A multicenter retrospective study
02
#e13022維迪西[xī]妥單抗[kànɡ]（RC48）治療HER2陽性晚[wǎn]期乳腺[xiàn]癌的有[yǒu]效性和[hé]安全性[xìnɡ]：來自[zì]中國的[de]真實世[shì]界經驗
Effectiveness and safety of disitamab vedotin (RC48) in pretreated HER2-positive advanced breast cancer: A real-world experience in China.
03
#e12636重組人[rén]源化抗[kànɡ]HER2抗體-MMAE結合物（RC48）用[yònɡ]于HER2陽性乳腺[xiàn]癌新輔助治療[liáo]的有效[xiào]性和安[ān]全性：一項單臂II期研究[jiū]
Efficacy and safety of recombinant humanized anti-HER2 antibody-MMAE conjugate (RC48) in neoadjuvant for HER2-positive breast cancer: A single-arm phase II study.
04
#e15003維迪西[xī]妥單抗[kànɡ]聯合呋[fū]喹替尼[ní]治療至[zhì]少兩種標準療[liáo]法難治[zhì]的HER2表[biǎo]達或HER2突變/擴增的[de]轉移性[xìnɡ]結直腸癌患者[zhě]：一項前瞻性[xìnɡ]、探[tàn]索性、單臂[bì]研究
Disitamab vedotin combined with fruquintinib in patients with HER2-expressing or HER2 mutation/amplified metastatic colorectal cancer refractory to at least two standard regimens: A prospective, exploratory, single-arm study.
#e16590維迪西[xī]妥單抗[kànɡ]聯合特[tè]瑞普利[lì]單抗新[xīn]輔助治[zhì]療肌層浸潤性[xìnɡ]膀胱癌[ái]后選擇性保膀[bǎnɡ]胱或根[ɡēn]治性膀[bǎnɡ]胱切除[chú]術的有[yǒu]效性和[hé]安全性[xìnɡ]
Efficacy and safety of neoadjuvant therapy with disitamab vedotin plus toripalimab in treating muscle invasive urothelial bladder cancer followed by selective bladder-preserving or radical cystectomy.
06
#e16614 HER2過表[biǎo]達的膀[bǎnɡ]胱癌（BC）的腫瘤[liú]免疫特[tè]征，以[yǐ]及對HER2過度表[biǎo]達的高[ɡāo]風險非[fēi]肌層浸[jìn]潤性BC的RC48-ADC對比[bǐ]卡介苗[miáo]的研究[jiū]
The tumor immune profile of bladder cancer (BC) with HER2 over-expression and the investigation into RC48-ADC versus BCG in high-risk non-muscle invasive BC with HER2 over-expression.
07
Preliminary results from a multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer (Hope-03).
08
#e16100維迪西[xī]妥單抗[kànɡ]（RC48）聯合卡[kǎ]瑞利珠[zhū]單抗和[hé]S-1用于HER2過表達的局部[bù]晚期胃[wèi]癌新輔助治療[liáo]的有效[xiào]性和安[ān]全性：一項前瞻性單臂II期研究[jiū]的初步[bù]結果
Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase II study.
#e16572維迪西[xī]妥單抗[kànɡ]（DV，RC48-ADC）聯合卡[kǎ]度尼利[lì]單抗（抗PD-1/CTLA-4雙特異[yì]性抗體）治療[liáo]局部晚[wǎn]期或轉移性尿[niào]路上皮[pí]癌（la/mUC）患者：一項開放標簽、單臂II期研究[jiū]
Disitamab vedotin (DV, RC48-ADC) combined with cadonilimab (anti-PD-1/CTLA-4 bispecific antibody) in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): An open-label, single-arm, phase II study.
10
Preliminary results from a phase II study to evaluate the efficacy and safety of perioperative disitamab vedotin (RC48-ADC) plus cadonilimab (AK104, PD-1/CTLA-4 bispecific antibody) for HER2-expressing muscle-invasive bladder cancer (MIBC).
![官方微[wēi]信](http://www.herfeir.com/uploadfile/2022/05/09/202205091142456SsE8C.jpg)